Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China.

[3] Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.

[2][better source needed] In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.

[4] Tucidinostat is being researched as a treatment for pancreatic cancer.

[5][6][7] However, it is not US FDA approved for the treatment of pancreatic cancer.